Silvia La Monica

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8893984/publications.pdf

Version: 2024-02-01

47 papers	1,914 citations	186209 28 h-index	254106 43 g-index
47 all docs	47 docs citations	47 times ranked	3080 citing authors

#	Article	IF	Citations
1	Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer. Cells, 2022, 11, 413.	1.8	21
2	YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs. JTO Clinical and Research Reports, 2022, 3, 100278.	0.6	3
3	EGFR Signaling in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Therapeutic Opportunities. Cells, 2022, 11, 1344.	1.8	1
4	Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib. Anti-Cancer Drugs, 2021, 32, 758-762.	0.7	9
5	Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review. Frontiers in Oncology, 2021, 11, 642190.	1.3	26
6	Inhibition of Human Malignant Pleural Mesothelioma Growth by Mesenchymal Stromal Cells. Cells, 2021, 10, 1427.	1.8	9
7	Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib Resistance. Cancers, 2021, 13, 3441.	1.7	8
8	Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry. Biochemical Pharmacology, 2021, 190, 114643.	2.0	11
9	A sulfonyl fluoride derivative inhibits EGFRL858R/T790M/C797S by covalent modification of the catalytic lysine. European Journal of Medicinal Chemistry, 2021, 225, 113786.	2.6	28
10	Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib. Cancers, 2021, 13, 6.	1.7	30
11	Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives. Critical Reviews in Oncology/Hematology, 2020, 146, 102820.	2.0	53
12	Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines. Frontiers in Oncology, 2020, 10, 563249.	1.3	18
13	Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 5165.	1.8	21
14	Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. Cancers, 2020, 12, 666.	1.7	24
15	Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation. Biochemical Pharmacology, 2019, 170, 113676.	2.0	64
16	Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion. Targeted Oncology, 2019, 14, 619-626.	1.7	33
17	Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells. Scientific Reports, 2019, 9, 13014.	1.6	62
18	Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. Journal of Experimental and Clinical Cancer Research, 2019, 38, 222.	3.5	45

#	Article	IF	Citations
19	Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. Frontiers in Oncology, 2019, 9, 179.	1.3	34
20	MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report. Translational Oncology, 2019, 12, 116-121.	1.7	37
21	The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells. Journal of Experimental and Clinical Cancer Research, 2018, 37, 72.	3.5	68
22	Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. Journal of Thoracic Oncology, 2018, 13, 810-820.	0.5	29
23	Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC. Journal of Thoracic Oncology, 2018, 13, e89-e91.	0.5	31
24	Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. Neoplasia, 2017, 19, 637-648.	2.3	81
25	New therapeutic strategies for malignant pleural mesothelioma. Biochemical Pharmacology, 2017, 123, 8-18.	2.0	38
26	Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines. Journal of Experimental and Clinical Cancer Research, 2017, 36, 174.	3.5	70
27	Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN. Oncotarget, 2017, 8, 53068-53083.	0.8	19
28	Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. Oncotarget, 2017, 8, 91841-91859.	0.8	28
29	Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR- Activating Mutation. Journal of Thoracic Oncology, 2016, 11, 1051-1063.	0.5	58
30	Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines. PLoS ONE, 2015, 10, e0141795.	1.1	51
31	Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. Molecular Cancer Therapeutics, 2015, 14, 1916-1927.	1.9	43
32	Physico-chemical characterization and biological evaluation of two fibroin materials. Journal of Tissue Engineering and Regenerative Medicine, 2014, 8, 874-885.	1.3	4
33	Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance. Molecular Cancer, 2014, 13, 143.	7.9	55
34	Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPKâ€“mTORC1 signaling. Breast Cancer Research and Treatment, 2013, 141, 67-78.	1.1	65
35	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer. Current Pharmaceutical Design, 2013, 19, 818-832.	0.9	24
36	Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification. PLoS ONE, 2013, 8, e78656.	1.1	39

#	Article	IF	Citations
37	Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. Cancer Letters, 2012, 323, 77-87.	3.2	78
38	Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines. Molecular Cancer, 2012, 11, 91.	7.9	35
39	Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines. Molecular Cancer, 2011, 10, 143.	7.9	36
40	Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Research and Treatment, 2010, 124, 79-88.	1.1	35
41	Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines. Biochemical Pharmacology, 2010, 80, 179-187.	2.0	31
42	Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion. Journal of Medicinal Chemistry, 2010, 53, 2038-2050.	2.9	49
43	Zoledronic acid determines S-phase arrest but fails to induce apoptosis in cholangiocarcinoma cells. Biochemical Pharmacology, 2009, 78, 133-141.	2.0	27
44	Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochemical Pharmacology, 2009, 78, 460-468.	2.0	71
45	Amino acid signaling through the mammalian target of rapamycin (mTOR) pathway: Role of glutamine and of cell shrinkage. Journal of Cellular Physiology, 2005, 204, 155-165.	2.0	61
46	Hematologic Malignancies With Extramedullary Spread of Disease. Journal of Clinical Oncology, 2003, 21, 1887-1888.	0.8	10
47	Human myeloma cells stimulate the receptor activator of nuclear factor-Î°B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood, 2002, 100, 4615-4621.	0.6	241